Back to results
US 2025/0361306 A1Published application
Antitumor immune checkpoint regulator antagonists
AssigneeGensun Biopharma Inc.
InventorsJackie SHENG, Margaret KAROW, Wei ZHANG
Life of this patent
Estimating the term…
Abstract
Antitumor antagonists that bind specifically to immune checkpoint regulator are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
Claims20
An antitumor antagonist comprising:
- a first targeting domain that specifically binds to PD-1, PD-L1 or LAG-3;
- and
- a second targeting domain comprising an scFv that specifically binds to TIGIT.
Dependencies are inferred from the claim text.